Proton Pump Inhibitor Therapy Associated with Lower Glycosylated Hemoglobin Levels in Type 2 Diabetes

References

1. 1.↵
   1. Cowie CC,
   2. Rust KF,
   3. Ford ES,
   4. et al

   . Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care 2009; 32: 287–94.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Shaw J,
   2. Sicree R,
   3. Zimmet P

   . Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2009; 87: 4–14.

   OpenUrlPubMed
3. 3.↵
   1. Mahler RJ,
   2. Adler ML.

   . Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endo Metab 1999; 84: 1165–71.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Bell DSH.

   . Current status of diabetes treatment. South Med J 2002; 95: 24–9.

   OpenUrlPubMed
5. 5.↵
   1. Mefford IN,
   2. Wade EU.

   . Proton pump inhibitors as a treatment method for type II diabetes. Medl Hypotheses 2009; 73: 29–32.

   OpenUrl
6. 6.↵
   1. Suarez-Pinzon WL,
   2. Yan Y,
   3. Rabinovitch A

   . Combination therapy with gastrin and glucagon-like peptide-1 (GLP-1) restores pancreatic insulin content and corrects hyperglycemia after diabetes onset in NOD mice. Can J Diabetes 2004; 28: 257.

   OpenUrl
7. 7.↵
   1. Rooman I,
   2. Lardon J,
   3. Bouwens L.

   . Gastrin stimulates B-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas. Diabetes 2002; 51: 686–90.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Cowey SL,
   2. Quast M,
   3. Belalcazar LM,
   4. et al

   . Abdominal obesity, insulin resistance and colon carcinogenesis are in creased in mutant mice lacking gastrin gene expression. Cancer 2005; 103: 2643–53.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Schubert ML,
   2. Makhlouf GM.

   . Neural, hormonal and paracrine regulation of gastrin and acid secretion. Yale J Biol Med 1992; 65: 553–60.

   OpenUrlPubMedWeb of Science
10. 10.↵
    1. Parkinson J.

    . A case of pernicious anaemia terminating in acute diabetes. Lancet 1910; II: 416–8.

    OpenUrl
11. 11.↵
    1. Rehfeld JF.

    . Disturbed islet-cell function related to endogenous gastrin release. J Clin Invest 1976; 58: 41–9.

    OpenUrlPubMed
12. 12.↵
    1. Rehfeld JF,
    2. Stadil F,
    3. Baden H,
    4. Fischermann K.

    . The enteral insulin-stimulation after Whipple's operation. Diabetologia 1975; 11: 207–10.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Bryant JG,
    2. Smith JV.

    . Zollinger-Ellison syndrome with pancreatic islet cell hyperplasia. Calif Med 1965; 102: 49–52.

    OpenUrlPubMed
14. 14.↵
    1. Meier JJ,
    2. Butler AE,
    3. Galasso R,
    4. Rizza RA,
    5. Butler PC.

    . Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 2006; 49: 2689–96.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Yoshihisa U.,
    2. Susumu I,
    3. Yasuyuki M,
    4. et al

    . Effect of serum gastrin concentration on insulin resistance. Digestion Absorption 2006; 28: 42–5.

    OpenUrl
16. 16.↵
    1. Creutzfeldt W.

    . The consequences of hypergastrinemia. Yale J Biol Med 1994; 67: 709–23.

    OpenUrl
17. 17.↵
    1. Gurden G,
    2. Boyacioglu S,
    3. Gul C,
    4. et al

    . Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2688–91.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Peach HG,
    2. Barnett NE.

    . Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Path 2001; 54: 466– 9.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Hu Y-M,
    2. Mei Q,
    3. Xu X-H,
    4. Hu X-P,
    5. Hu N-Z,
    6. Xu J-M.

    . Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 2006; 12: 4750–3.

    OpenUrlPubMed
20. 20.↵
    1. Ligumsky M,
    2. Lysy J,
    3. Siguencia G,
    4. Friedlander Y.

    . Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001; 33: 32–5.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Cadiot G,
    2. Vissuzaine C,
    3. Pospai D,
    4. Ruszniewski P,
    5. Potet F,
    6. Mignon M.

    . Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Gastroenterol Clin Biol 1995; 19: 811–7.

    OpenUrlPubMed
22. 22.↵
    1. Koop H,
    2. Klein M,
    3. Arnold R.

    . Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Therap 1990; 4: 131–8.

    OpenUrlPubMedWeb of Science
23. 23.↵
    1. Vanderhoff BT,
    2. Tahboub RM.

    . Proton pump inhibitors: an update. Am Fam Physician 2002; 66: 273–80.

    OpenUrlPubMedWeb of Science
24. 24.↵
    1. Sanders SW,
    2. Tolman KG,
    3. Greski PA,
    4. Jennings DE,
    5. Hoyos PA,
    6. Page JG.

    . The effects of lansoprazole, a new H+, K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 359–72.

    OpenUrlPubMedWeb of Science
25. 25.↵
    1. Banerjee S,
    2. Ardill JES,
    3. Beattie AD,
    4. McColl KEL.

    . Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Aliment Pharmacol Ther 1995; 9: 507–12.

    OpenUrlPubMed
26. 26.↵
    1. Suzaki F,
    2. Suzuki R,
    3. Sugiyama M.

    . An increase of serum insulin by induced hypergastrinemia with proton pump inhibitor in type 2 diabetes. Prog Med 2004; 24: 661–4.

    OpenUrl